Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Purpose

This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.

Conditions

  • Endometrial Carcinoma
  • Endometrial High Grade Endometrioid Adenocarcinoma
  • Stage II Endometrial Cancer
  • Stage III Endometrial Cancer
  • Stage IV Endometrial Cancer

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years - Planned complete surgical staging at Mayo Clinic. Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon's discretion - At least one preoperative or postoperative feature of aggressive disease [International Federation of Gynecology and Obstetrics (FIGO) staging used throughout this protocol] - Preoperatively: - Biopsy with grade 3 endometrioid endometrial cancer (EC) or non-endometrioid EC - Patients with FIGO grade 1-2 EC with evidence of extrauterine disease on imaging (CT, MRI, or PET) - Postoperatively: - Endometrial cancer (FIGO) with one or more established risk factors: - Non-endometrioid histology - Grade 3 - Lymphovascular space invasion (LVSI), ≥ 50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node OR - Stage II to IV (FIGO) EC - Provide written informed consent - Willingness to provide mandatory blood specimens for correlative research - Willingness to provide mandatory tissue specimens for correlative research - Willingness to return to registering site for clinical follow-up

Exclusion Criteria

  • Patient receiving or who has received neoadjuvant chemotherapy - Pre-operative pregnancy

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Observational Patients undergo blood and tissue sample collection and have their medical records reviewed throughout the study.
  • Other: Non-Interventional Study
    Non-interventional study

Recruiting Locations

Mayo Clinic in Rochester
Rochester, Minnesota 55905
Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu

More Details

Status
Recruiting
Sponsor
Mayo Clinic

Study Contact

Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu

Detailed Description

PRIMARY OBJECTIVE: I. To generate preliminary data for a risk stratification model for recurrence including traditional histopathologic risk factors, molecular characterization in endometrial cancer patients with features of aggressive disease. OUTLINE: This is an observational study. Patients undergo blood and tissue sample collection and have their medical records reviewed throughout the study.